Biotechnology companies experienced a great amount of growth and success toward the end of 2019. Then when the COVID-19 pandemic began, the growth slowed and knocked down companies just as rapidly. However, unlike other industries, biotech companies have soared back to the levels they were previously at before the pandemic, and have even exceeded numbers in some situations. The stock futures don’t appear to be changing for the worse anytime soon for them either. These four biotech stocks have at least a 30% gain year-to-date and could continue seeing success for the rest of 2020 and beyond.
Vertex Pharmaceuticals is a stable company known for making major splashes in their industry. One of their newest drugs is called Trikafta and it is used for patients suffering from cystic fibrosis. The revenue in the first quarter of sales from Trikafta was nearly $900 million and became the leader in the market in the United States. What makes Vertex Pharmaceuticals most attractive for investors is their stability, as they have no long-term debt and have more than $4 billion in cash.
Emergent BioSolutions has placed a large focus on developing treatments and vaccines to neutralize or treat various public health threats, such as cholera, anthrax, smallpox, and more. It has also been involved with COVID-19 therapies, but it has not been their primary focus. The stock futures for Emergent BioSolutions are promising. However, investors need to look closely at its balance sheet, which shows about four times as much long-term debt as current available cash.
Exelixis is a company name to watch closely as it focuses on drugs and treatments to fight various types of cancer. Cancer treatments have long been the focus of certain biotech companies since there are no known effective options available. But with the combination of Exelixis’ reputation and great financial position, the stock futures look very promising and could be a great investment opportunity for the right investor.
Regeneron Pharmaceuticals has been prominent in the fight against COVID-19, but the company roots go much deeper than this. Its most recent development has been a treatment for asthma and eczema, as well as a treatment for various eye diseases. These two treatments (Dupixent and Eylea) are expected to drive growth for Regeneron Pharmaceuticals for years to come and may even exceed lofty expectations. Plus, its budget is one of the largest among other biotech companies, leaving plenty of room to grow.
At Stock Investing Info, we know investors can discover financial success with biotech stocks. The industry offers plenty of room to diversify as well, so you can manage your risk tolerance accordingly. As emerging technologies continue to be developed, biotech companies appear to be the beneficiaries and will continue thriving. If you’re looking to diversify your portfolio with thriving biotech stocks, contact us and we would be happy to discuss various options with you.